ReviewInternational journal of nanomedicine2026
Nanobiotic-Enhanced Probiotics for Targeted Gut Delivery: Mechanisms, Therapeutic Applications, and Translational Challenges.
Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The gut microbiota plays a pivotal role in maintaining human health by influencing physiological processes such as digestion, immune regulation, and metabolism. However, disruptions in gut microbial balance, or dysbiosis, are associated with numerous disorders. Probiotics have emerged as potential therapeutic agents, but their efficacy is limited by challenges such as low survival during gastrointestinal transit, poor colonization, and lack of targeted delivery. Nanotechnology has recently provided promising solutions to these limitations by enhancing the stability, viability, and functionality of probiotics. To provide an updated perspective, this article presents a structured narrative review informed by a PRISMA-guided literature search and screening process. Relevant studies published between 2021 and 2025 were identified from PubMed, Scopus, IEEE Xplore, and Google Scholar and were narratively synthesized to examine nanoencapsulation strategies, hybrid nanobiotic systems, smart delivery platforms, therapeutic applications, and translational barriers. Nanoencapsulation techniques, hybrid nanobiotic systems, and smart delivery platforms are at the forefront of probiotic enhancement. These systems improve protection of probiotics against harsh gastric conditions and enable targeted release within specific regions of the gastrointestinal tract, thereby enhancing colonization efficiency and therapeutic potential. Moreover, nanobiotics show promise in modulating gut microbiota composition, strengthening immune responses, and opening new therapeutic avenues for the management of gastrointestinal disorders, metabolic diseases, and immune-related conditions. Despite these advances, challenges related to safety, scalability, and regulatory approval remain significant barriers to clinical translation. This review synthesizes recent progress in nanobiotic-enhanced probiotics, evaluates their therapeutic applications, and discusses key challenges and future directions for precision microbiome therapeutics.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.